Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
DTIL Stock Chart & Stats
$5.11
-$0.10(-2.09%)
At close: 4:00 PM EST
$5.11
-$0.10(-2.09%)
Day’s Range― - ―
52-Week Range$3.61 - $8.82
Previous CloseN/A
Volume55.33K
Average Volume (3M)123.92K
Market Cap
$88.69M
Enterprise Value$13.60M
Total Cash (Recent Filing)$44.87M
Total Debt (Recent Filing)$29.13M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 17, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding13,256,751
10 Day Avg. Volume185,671
30 Day Avg. Volume123,923
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.46
Price to Sales (P/S)0.38
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue19.48
Enterprise Value/Gross Profit-20.23
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$45.00Price Target Upside780.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceELIMINATE-B paired biopsy data provides the first clinical evidence of in vivo gene editing in chronic HBV, confirming ARCUS is driving durable antiviral effects by directly modifying viral DNA within infected hepatocytes.
Regulatory ProgressPrecision strengthened its PBGENE-HBV intellectual property and was issued a patent for 'optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B Virus genome' by the U.S. Patent and Trademark Office providing U.S. patent protection into 2042.
Safety ProfileNo patient experienced serious adverse events or significant lab abnormalities in liver enzymes and platelets, indicating a favorable safety profile for PBGENE-HBV.
Bears Say
Access BarriersDespite scientific progress, it was emphasized that many families—particularly those in rural or resource-limited settings—continue to face delayed diagnosis, fragmented access to specialized centers, and financial barriers that limit participation in clinical trials or access to novel therapies.
Treatment Effectiveness ConcernsThe company has not set any baseline limits for HBsAg levels, which could complicate treatment effectiveness for some patients.
Trial Participation ChallengesSome families still encounter initial misdiagnoses or are forced to choose between attending clinic visits and maintaining employment or basic household stability.
Precision BioSciences News
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.61 and its highest was $8.82 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $88.69M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is Mar 17, 2026 which is in 108 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Nov 03, 2025. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.5.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -0.6.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 13,256,751 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$1.84 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -9.804%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
Precision BioSciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (780.63% Upside)
$45.00 (780.63% Upside)
Hedge Fund Trend
Decreased
By 426.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.3%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.91%
12-Months-Change
Fundamentals
Return on Equity
-205.16%
Trailing 12-Months
Asset Growth
-34.30%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc. (DTIL) is a biotechnology company that specializes in gene editing and genetic medicine. The company is primarily focused on developing advanced therapeutic solutions using its proprietary ARCUS technology, which is designed to create precision genetic modifications in various organisms, including human cells. Precision BioSciences operates in sectors such as gene therapy, cell therapy, and agricultural biotechnology, and is working towards addressing significant unmet medical needs in areas like oncology and genetic disorders.
DTIL Stock 12 Month Forecast
Average Price Target
$45.00
▲(780.63% Upside)
Technical Analysis
Bluebird Bio
―
CytomX Therapeutics
―
Adicet Bio
―
ImageneBio
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
3.16% Insiders
5.11% Mutual Funds
8.82% Other Institutional Investors
79.56% Public Companies and
Individual Investors